Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

Medicine & Life Sciences

• Oncogene Proteins 100%
• Fluorescence In Situ Hybridization 90%
• Immunohistochemistry 61%
• Breast Neoplasms 56%
• Gene Amplification 52%
• erbB-2 Genes 24%
• Waxes 11%
• Trastuzumab 10%
• Triage 9%
• Proteins 9%
• United States Food and Drug Administration 8%
• Oncogenes 8%
• Formaldehyde 8%
• Paraffin 8%
• Breast 6%
• Monoclonal Antibodies 6%
• Drug Therapy 5%
• Antibodies 4%
• Therapeutics 1%